Multiple myeloma

The PBS subsidises lenalidomide and pomalidomide for patients with multiple myeloma.

Patient eligibility

Treatment with bortezomib can be subsidised through the PBS under the National Health Act 1953, section 100 arrangements - Efficient Funding of Chemotherapy (EFC), for a patient with multiple myeloma.

Treatment with lenalidomide and pomalidomide can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, section 100 arrangements - Highly Specialised Drug (HSD) Program, for a patient with multiple myeloma.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines restrictions for prescribing bortezomib, lenalidomide and pomalidomide.

Section 100 arrangements

Lenalidomide and pomalidomide 

These items are only available for a day admitted patient, non-admitted patient or patients on discharge who are attending:

  • an approved private hospital
  • a participating public hospital, or
  • a public hospital

These items aren't PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Applications

Bortezomib

From 1 October 2018, treatment with bortezomib is Authority Required (Streamlined) and doesn’t require prior authority approval from us for listed quantities and repeats.

Lenalidomide

Initial treatment - newly diagnosed

Patients receiving lenalidomide under this PBS listing must be registered in the i-access risk management program. Read more on the Celgene website or call Celgene on 1800 235 436.

Make all initial applications for authority approval to prescribe PBS subsidised lenalidomide for the treatment of newly diagnosed multiple myeloma in writing and:

Initial applications must include the completed:

Initial treatment - progressive disease

Patients receiving lenalidomide under this PBS listing must be registered in the i-access risk management program. Read more on the Celgene website or call Celgene on 1800 235 436.

Make all initial applications for authority approval to prescribe PBS subsidised lenalidomide for the treatment of progressive multiple myeloma in writing and:

Initial applications must include the completed:

Continuing treatment

To make continuing applications for treatment with PBS subsidised lenalidomide call the PBS Complex Drugs Programs enquiry line.

Pomalidomide

Initial treatment

Patients receiving pomalidomide under this PBS listing must be registered in the i-access risk management program. Read more on the Celgene website or call Celgene on 1800 235 436.

Make all initial applications for authority approval to prescribe PBS subsidised pomalidomide for the treatment of multiple myeloma in writing and:

Initial applications must include the completed:

Continuing treatment

To make continuing applications for treatment with PBS subsidised pomalidomide for patients, call the PBS Complex Drugs Programs enquiry line.

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 October 2018